ISSN: 1859 - 2872
The correlation between lipid disorder and serum glucagon like peptide-1 in newly-diagnosed type 2 diabetes mellitus patients with either overweight or obesity
Main Article Content
Keywords
Abstract
Objective: To measure the percentage of lipid disorders and the relation between it and serum glucagon like peptide-1 levels among newly-diagnosed type 2 diabetes mellitus patients with either comorbid overweight or obesity. Subject and method: A descriptional and cross-sectional study on 66 newly-diagnosed inpatients with type 2 diabetes mellitus and either comorbid overweight or obesity in the National Endocrinology Hospital. Result: Mean levels and the proportion of patients for each lipid disorder features were as follows: 3.01 ± 2.18mmol/l and 69.7% for triglyceride, 5.49 ± 1.34mmol/l and 60.6% for cholesterol, 3.27 ± 1.03 and 43.9% for LDL-C, and 1.20 ± 0.33 and 16.7% for HDL-C; the overall proportion of patients with lipid disorders regardless to specified features was 84.8%. There was a moderate positive correlation between fasting serum GLP-1 and triglyceride levels (r = 0.367), and a moderate negative correlation with LDL-C (r = -0.312). There was a strong positive correlation between serum GLP-1 after oral administration 75-grams of glucose and triglyceride (r = 0.647). Conclusion: Type 2 diabetes mellitus patients with either overweight or obesity suffered from a high percentage of overall lipid disorders (84.8%) which mostly due to hypertriglyceridemia (69.7%). There was a significant positive linear relationship between serum GLP-1 levels and triglyceride and a negative linear relationship with LDL-C.
Article Details
References
2. Nguyễn Thị Phi Nga (2009) Nghiên cứu nồng độ TNFα, CRP huyết thanh và liên quan với hình thái, chức năng động mạch cảnh gốc bằng siêu âm Doppler mạch ở BN ĐTĐ týp 2. Luận án Tiến sỹ Y học, Học viện Quân y.
3. Nguyễn Thị Thu Thảo (2012) Nghiên cứu đặc điểm lâm sàng và tình trạng kháng insulin trên bệnh nhân đái tháo đường týp 2 mới chẩn đoán. Luận án Tiến sĩ Y học, Học viện Quân y.
4. ADA (2012) Standards of medical care in diabetes - 2012. Diabetes Care 35(1): 11-63.
5. Diva De Leon, Michael Crutchlow et al (2006) Role of GLP-1 in the pathogenthesis and treatment of diabetes mellitus. The International Journal of Biochemistry and Cell Biology 38: 845-859.
6. Fang Zhang, Xialian Tang, Hongyl Cao et al (2012) Impaired secretion of total GLP-1 in people with impaired fasting glucose combined impaired glucose tolerance. Medical Sciences 9(7): 574-581.
7. Marjan A et al (2013) Preserved GLP-1 and exaggerated GIP in type 2 diabetes and relationships with triglycerides and ALT. Endocrinology 169: 421-430.
8. Gavigan AK and Murphy KG (2012) Gut hormones: The future of obesity treatment?. Bristish Journal of Clinical Pharmacology 74(6): 911-919.
9. Katia Piotrowski et al (2013) Circulating concentration of GLP-1 are associated with coronary atherosclerosis in humans. Cardiovascular Diabetology 12(117): 1-7.
10. Tojo MY, Tojo T and Takahira N (2010) Elevated circulating levels of an incretin hormone, GLP-1, are associated with metabolic components in high - risk patients with cardiovascular disease. Cardiovascular Diabetology 9(17): 1- 10.
Article Sidebar
